AbbVie’s New Data Confirms Atogepant (QULIPTA®) for Long-Term Migraine Prevention
AbbVie (NYSE: ABBV) has revealed interim findings from an ongoing Phase 3 extension study, spanning 156 weeks, investigating the sustained safety and tolerability of oral atogepant for migraine prevention in…
Orion Research Assistants Striving to Combat Cancer and Alleviate Pain: “Our Breakthrough Discovery Holds Promise for Shaping Future Research
Mira Leppänen-Mattelmäki, a Research Associate in Orion’s pain team, finds her greatest motivation in the potential impact their work may have on patients. For Minna Vuorenmaa, a Research Assistant in…
Jazz Pharmaceuticals Set to Unveil Broad Range of Neuroscientific Innovations at American Academy of Neurology’s Annual Gathering
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has revealed that it will present 13 abstracts from its extensive neuroscience portfolio and pipeline at the 76th Annual American Academy of Neurology Meeting (AAN),…
FDA Grants Emergency Use Authorization to Labcorp for Home Collection of Mpox PCR Test
Labcorp (NYSE: LH), a leading provider of innovative laboratory services globally, has announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Mpox…
Selecting the Ideal Allergy Medication for Your Seasonal Symptoms
For allergy sufferers, the season of congestion, sneezing, watery eyes, scratchy throats, and runny noses has arrived earlier than usual this year. But there’s still time to alleviate those symptoms…
Vertex Strikes Deal to Purchase Alpine Immune Sciences
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive…
World Health Organization Raises Concern Over Viral Hepatitis: 3,500 Lives Lost Daily
The latest Global Hepatitis Report by the World Health Organization (WHO) for 2024 reveals a concerning rise in deaths attributed to viral hepatitis. This disease now stands as the second…
WHO to Release New Guidelines for Simultaneous Treatment of Drug-Resistant Tuberculosis and Hepatitis C
In a recent announcement, the World Health Organization (WHO) has provided updates regarding the simultaneous treatment of drug-resistant tuberculosis (TB) and hepatitis C (HCV). The latest evidence suggests that administering…
Teva’s First Quarter 2024 Financial Results Conference Call Scheduled for May 8th at 8 a.m. ET
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its plans to unveil the financial results for the first quarter of 2024 on Wednesday, May 8, 2024, at 7:00…
Pfizer Reveals Encouraging Phase 3 Findings of ABRYSVO® in High-Risk Adults (Ages 18-59) Vulnerable to RSV Disease
Pfizer Inc. (NYSE: PFE) has reported promising top-line data on the immunogenicity and safety of ABRYSVO® from its pivotal Phase 3 clinical trial MONeT (RSV IMmunizatiON Study for AdulTs at…
SkinMedica® Revolutionizes Acne Care for Clear Skin Confidence
Allergan Aesthetics, a subsidiary of AbbVie Inc. (NYSE: ABBV), has unveiled two new additions to the SkinMedica® lineup, developed by the creators of BOTOX® Cosmetic. These groundbreaking products, the SkinMedica®…
BridgeBio Pharma: CMR Imaging Supports Clinical Improvement in ATTR-CM Trial
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading biopharmaceutical company specializing in genetic diseases and cancers, unveiled findings from the exploratory CMR imaging substudy of its Phase 3 trial, ATTRibute-CM, evaluating…